# Consideration of spatial companion biomarkers for targeted therapeutics in cancer: depatuxizumab mafodotin in glioblastoma

**Authors:** Rimas V. Lukas, Ruochen Du, Harrshavasan Congivaram, Kathleen McCortney, Karan Dixit, Craig Horbinski, Margaret Schwartz, Raymond Lezon, Lauren Singer, Ditte Primdahl, Jigisha Thakkar, Amy B. Heimberger, Roger Stupp, Priya Kumthekar

PMC · DOI: 10.1172/jci.insight.198475 · JCI Insight · 2026-02-03

## TL;DR

This study investigates how EGFR expression in glioblastoma tumors affects treatment outcomes with depatuxizumab mafodotin.

## Contribution

The study explores the use of EGFR as a spatial companion biomarker for targeted cancer therapy in glioblastoma.

## Key findings

- The relationship between tumor EGFR expression and outcomes was explored in glioblastoma patients.
- Depatuxizumab mafodotin was evaluated in an expanded access program for progressive glioblastoma.

## Abstract

An expanded access program of depatuxizumab mafodotin for patients with progressive glioblastoma explores the relationship between tumor EGFR expression and outcomes.

## Linked entities

- **Genes:** EGFR (epidermal growth factor receptor) [NCBI Gene 1956]
- **Diseases:** glioblastoma (MONDO:0018177)

## Full-text entities

- **Diseases:** glioblastoma (MESH:D005909), cancer (MESH:D009369)
- **Chemicals:** depatuxizumab mafodotin (MESH:C000631685)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13043081/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13043081/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC13043081/full.md

---
Source: https://tomesphere.com/paper/PMC13043081